Why ChondroFiller is not available on the NHS

ChondroFiller is not available on the NHS, and there is currently no route to obtain it through NHS funding in England. The reason is structural rather than clinical.

NHS commissioning of new treatments in England is governed by the National Institute for Health and Care Excellence (NICE) through a formal health technology appraisal (HTA) process. Until a treatment completes that process and receives a positive appraisal, no GP referral framework exists to receive or route patients towards it, and NHS trusts have no commissioning basis on which to fund it. ChondroFiller has not entered the NICE HTA process.

For patients wondering whether an Individual Funding Request (IFR) to their local NHS trust might offer a workaround, the evidence is discouraging: there is currently no established precedent of an IFR being approved for ChondroFiller, making this an unreliable avenue to pursue.

For context, the only articular cartilage therapy that has cleared the NICE route is Autologous Chondrocyte Implantation (ACI), approved under Technology Appraisal TA477 in October 2017. ACI is a theatre-based surgical procedure — mechanistically and procedurally distinct from ChondroFiller's outpatient injection model — and TA477 does not extend to it.

Importantly, the absence of an NHS pathway reflects where ChondroFiller sits in the regulatory-commissioning pipeline, not a NICE rejection of its safety or clinical evidence. Commissioning decisions routinely lag several years behind CE marking and early clinical adoption for Class III regenerative devices.

How the private access pathway works

Unlike most specialist treatments in the UK, ChondroFiller requires no GP referral, no consultant letter, and no trust approval. Access is entirely private and self-funded, which means the patient controls the timeline from the outset.

The typical journey begins with a patient identifying a clinic that offers ChondroFiller as an outpatient injection and contacting it directly to arrange an initial assessment. That assessment involves a clinical consultation and a review of existing imaging — usually MRI — to establish whether the character of the defect makes the patient a suitable candidate. No treatment decision is made before that stage is complete; the assessment exists precisely to confirm suitability rather than to proceed automatically.

This stands in practical contrast to the NHS pathway, where a GP referral initiates the process and the patient moves through a sequence of authorisations before reaching a specialist. Under the self-referral model, patients who already have relevant imaging can often move to assessment relatively quickly, and those who have been through an NHS diagnostic workup can bring that material with them.

At present, a small number of specialist musculoskeletal clinics across the UK offer ChondroFiller as an outpatient injection — it is not yet widely available, and confirming that a clinic offers the treatment specifically should be part of any initial enquiry.

What the treatment involves as an outpatient procedure

The appointment itself takes place at a specialist musculoskeletal clinic as a standard outpatient procedure, typically lasting 30 to 45 minutes. No incision is made, no general anaesthetic is used, and no theatre admission is required.

ChondroFiller is a cell-free Type I collagen hydrogel — a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany and imported into the UK under prescription. It is supplied as a liquid in a two-chamber syringe and placed into the affected joint under real-time ultrasound guidance, allowing precise positioning within the focal defect. Once inside the joint, the product self-polymerises — setting into a dimensionally stable gel within approximately three to five minutes — and physically occupies the defect space.

The clinical mechanism is acellular matrix-induced chondrogenesis: the gel scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, supporting the body's own repair processes rather than introducing any external cells. Over time, those recruited cells begin to lay down repair tissue within the scaffold.

After the injection, patients follow a structured rehabilitation programme. This is markedly different from the recovery protocols associated with surgical cartilage procedures such as ACI, which involve theatre admission and a longer post-operative rehabilitation arc. Surgery remains a separate alternative pathway for patients outside the injectable indication or where scaffold treatment alone is insufficient.

Which patients are typically assessed for ChondroFiller

Suitable candidates share one defining characteristic: a focal cartilage defect rather than widespread joint deterioration. ChondroFiller is indicated for Grade III or IV articular cartilage lesions — areas of significant damage that are contained rather than diffuse — in joints including the knee, hip, ankle, shoulder, and wrist.

Patients with diffuse, end-stage osteoarthritis fall outside the indication. This distinction matters clinically, not just definitionally. In a prospective hip cohort study following 26 patients over three to five years, those with pre-existing Tönnis grade 2–3 osteoarthritis (advanced, joint-wide disease) had poor outcomes, while 17 of 21 patients with focal lesions achieved good or excellent results. The treating specialist will assess hip patients in particular against this finding at consultation.

There is no published upper age limit, and no restriction on defect size for the injection pathway. What determines suitability is the character of the defect — whether it is contained, how the surrounding cartilage and bone look on imaging, and the patient's overall joint health — rather than age alone.

Because some patients presenting with cartilage symptoms turn out to have broader joint disease, the initial assessment stage exists precisely to draw this distinction. Imaging, usually MRI, characterises the defect before any treatment decision is made. Where ChondroFiller is not appropriate, the specialist can discuss alternative pathways at the same appointment.

Costs, what is included, and private insurance

Budgeting for ChondroFiller is more predictable than for many private treatments, because specialist clinics typically bundle everything into a single all-inclusive figure. That package generally covers the initial consultation, real-time ultrasound guidance, the collagen scaffold product itself, intravenous antibiotic cover, and a follow-up appointment at around six weeks — so patients face one known cost rather than a sequence of itemised bills.

The pricing structure is tiered by the volume of scaffold product required, which reflects the size and number of focal lesions being treated, not the joint involved. A smaller, single-defect presentation requires one box of product; larger or more complex presentations require two or three. Guide costs vary between clinics, and patients should ask for a full written cost breakdown at their assessment appointment before committing.

On the insurance side, major UK private medical insurers — including Bupa and AXA — do not routinely cover ChondroFiller as a standard benefit. Some clinics can provide an itemised invoice if a patient wishes to submit a claim independently, but coverage cannot be assumed. Anyone planning to rely on PMI should verify their position in writing with their insurer before booking, not after.

There is no NHS co-payment mechanism, partial funding route, or back-channel that reduces what the patient pays. The full treatment cost is borne privately.

What the clinical evidence shows and where gaps remain

Three clinical datasets give the clearest picture of what ChondroFiller can and cannot be expected to do.

In a multicentre randomised study comparing ChondroFiller with microfracture for focal knee cartilage defects, patients in the ChondroFiller group showed meaningful, statistically significant improvement in IKDC function and symptom scores at three and six months, sustained to twelve months. MRI at follow-up confirmed good defect filling and progressive cartilage maturation. No adverse events were reported. The hip cohort data, discussed in the previous section, follows a similar direction over a longer horizon. A 2025 study of ChondroFiller used in wrist cartilage defects found treated patients had significantly better cartilage quality at follow-up arthroscopy than untreated controls — Outerbridge scores of 1.5 versus 3 (P=0.006) and ICRS grades of 1 versus 3 (P=0.002). Separately, a 2025 ex vivo explant study recorded a 2.4-fold increase in DNA content within the scaffold by day 14, supporting the cell-recruitment mechanism at a biological level rather than only through clinical scores.

The gaps in this picture are equally real and should not be read past quickly. The knee randomised trial enrolled 13 patients in the ChondroFiller arm and 10 in the comparator arm — too few to draw definitive conclusions. No large, multicentre RCT has been completed. UK-specific outcomes data does not yet exist in the published literature.

Taken together, the evidence supports cautious confidence in the treatment for well-selected patients with focal defects, while making clear that the scale of data needed for NHS-level validation has not yet been accumulated.